Effects of Toxic Substances on the Heart

  • Victor J. Ferrans
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 34)


The reactions of the heart to toxic injury can be classified according to whether they represent: (a) a direct toxic effect of the agent, (b) the result of an exaggeration of the pharmacologic effects of the agent either on the myocardium itself or on the coronary or systemic circulation, or (c) an allergic or hypersensitivity phenomenon. These etiologic distinctions are not always clear on anatomic study of the heart lesions resulting from toxic injury, as a wide spectrum of complex cardiac morphologic changes has been associated with the effects of toxic drugs and chemicals on humans and on experimental animals.


Cardiac Hypertrophy Cardiac Muscle Cell Coagulation Necrosis Contraction Band Congestive Cardiomyopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ferrans VJ: Morphology of the heart in hypertrophy. Hosp Pract 18: 67–78, 1983.Google Scholar
  2. 2.
    Oberpriller JO, Ferrans VJ, Carroll RJ: Changes in DNA content, number of nuclei and cellular dimensions of young rat atrial myocytes in response to left coronary ligation. J Mol Cel Cardiol 15: 31–42, 1983.CrossRefGoogle Scholar
  3. 3.
    Powis L: Growth hormone in cardiac hypertrophy induced by nephrogenous hypertension. Recent Adv Stud Cardiac Struct Metab 8: 413–425, 1975.PubMedGoogle Scholar
  4. 4.
    Gerdes AM, Kriseman J, Bishop SP: Changes in myocardial cell size and number during development and reversal of hyperthyroidism in neonatal rats. Lab Invest 48: 598–602, 1983.PubMedGoogle Scholar
  5. 5.
    Symons C, Olsen EGJ, Hawkey CM: The production of cardiac hypertrophy by triiodothyroacetic acid. J Endocrinol 65: 341–346, 1975.PubMedCrossRefGoogle Scholar
  6. 6.
    Hawkey CM, Olsen EGJ, Symons C: Production of cardiac muscle abnormalities in offspring of rats receiving triiodothyroacetic acid (triac) and the effect of beta adrenergic blockade. Cardiovasc Res 15: 196205, 1981.Google Scholar
  7. 7.
    Laks MM, Morady F: Norepinephrine—the myocardial hypertrophy hormone? Am Heart J 91: 674675, 1976.Google Scholar
  8. 8.
    Bartolome JV, Trepanier PA, Chait EA, Slotkin TA: Role of polyamines in isoproterenol-induced cardiac hypertrophy: effects of a-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. J Mol Cell Cardiol 14: 461–466, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Roberts WC, Ferrans VJ: Pathologic anatomy of the cardiomyopathies (idiopathic dilated and hypertrophic types, infiltrative types and endomyocardial disease with and without eosinophilia). Hum Pathol 6: 287–342, 1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Perloff JK: Pathogenesis of hypertrophic cardiomyopathy: hypotheses and speculations. Am Heart J 101: 219–226, 1981.PubMedCrossRefGoogle Scholar
  11. 11.
    Liu SK: Cardiac disease in the dog and cat. In: Roberts HR, Dodds WJ (eds) Pig model for biomedical research. Taipei: Pig Research Institute, 1982, pp 110–133.Google Scholar
  12. 12.
    Hsu FS, Du S-J: Cardiac diseases in swine. In: Roberts HR, Dodds WJ (eds) Pig model for biomedical research. Taipei: Pig Research Institute, 1982, pp 134–142.Google Scholar
  13. 13.
    Ferrans VJ, Buja LM, Roberts WC: Cardiac morphologic changes produced by ethanol. In Rothschild MA, Oratz M, Schreiber S (eds) Alcohol and abnormal protein biosynthesis. New York: Pergamon, 1974, pp 139–185.Google Scholar
  14. 14.
    Regan TJ, Khan MI, Ettinger PO, Heider B, Lyons MM, Oldewurtel HA: Myocardial function and lipid metabolism in the chronic alcoholic animal. J Clin Invest 54: 740–752, 1974.PubMedCrossRefGoogle Scholar
  15. 15.
    Opie LH: Metabolic and drug-induced injury to the myocardium. In: Bristow MR (ed) Drug-induced heart disease. Amsterdam: Elsevier/North Holland Biomedical, 1980, pp 81–102.Google Scholar
  16. 16.
    Ferrans VJ, Butany JW: Ultrastructural pathology of the heart. In: Trump BF, Jones RT (eds) Diagnostic electron microscopy, vol 4. New York: John Wiley and Sons, 1983, pp 319–473.Google Scholar
  17. 17.
    Ferrans VJ: Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62: 955–961, 1978.PubMedGoogle Scholar
  18. 18.
    Ferrans VJ: Morphologic assessment of cardiac lesions caused by anthracyclines. In: Muggia FM, Young CW, Carter SK (eds) Anthracycline antibiotics in cancer therapy. The Hague: Martinus Nijhoff, 1982, pp 331–347.CrossRefGoogle Scholar
  19. 19.
    Ferrans VJ: Anthracycline cardiotoxicity. In Spitzer JJ (ed) Myocardial injury. New York: Plenum, 1982, pp 519–532.Google Scholar
  20. 20.
    Billingham ME, Mason JW, Bristow MR, Daniels JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865872, 1978.Google Scholar
  21. 21.
    Herman EH, Ferrans VJ, Jordon W, Ardalan B: Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31: 85–97, 1981.PubMedGoogle Scholar
  22. 22.
    Herman EH, Ferrans VJ: Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187). Cancer Res 41: 3436–3440, 1981.PubMedGoogle Scholar
  23. 23.
    Herman EH, El-Hage AN, Ferrans VJ, Witiak DT: Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol 40: 217–231, 1983.PubMedGoogle Scholar
  24. 24.
    Herman EH, Ferrans VJ: Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine Lab Invest 49: 69–77, 1983Google Scholar
  25. 25.
    Van Vleet JF, Ferrans VJ, Weirich WE: Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 99: 13–32, 1980.Google Scholar
  26. 26.
    Van Vleet JF, Ferrans VJ: Cutaneous lesions and hematologic alterations in chronic adriamycin intoxication in dogs with and without vitamin E and selenium supplementation. Am J Vet Res 41: 69 1699, 1980.Google Scholar
  27. 27.
    Van Vleet JF, Ferrans VJ: Evaluation of vitamin E and selenium protection against chronic adriamycin toxicity in rabbits. Cancer Treat Rep 64: 315–317, 1980.Google Scholar
  28. 28.
    Unverferth DV, Mehegan JP, Nelson RW, Scott CC, Leier CV, Hamlin RL: The efficacy of N-acetylcysteine in preventing doxorubicin-induced cardiomyopathy in dogs. Semin Oncol (Suppl 1 ) 10: 2–6, 1983.Google Scholar
  29. 29.
    Applebaum FR, Strauchen JA, McGraw RG, Jr, Savage DD, Kent KM, Ferrans VJ, Herzig GP: Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Lancet 1: 58–62, 1976.CrossRefGoogle Scholar
  30. 30.
    Gottdiener JS, Applebaum FR, Ferrans VJ, Deisseroth A, Ziegler J: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141: 758–763, 1981.PubMedCrossRefGoogle Scholar
  31. 31.
    Von Hoff DD, Rozencweig M, Piccart M: The cardiotoxicity of anticancer agents. Semin Oncol 9: 2333, 1982.Google Scholar
  32. 32.
    Jankus EF, Noren GR, Staley NA: Furazolidone-induced cardiac dilatation in turkeys. Avian Dis 16: 958–961, 1972.PubMedCrossRefGoogle Scholar
  33. 33.
    Czarnecki CM: Furazolidone-induced cardiomyopathy: biomedical model for the study of cardiac hypertrophy and congestive heart failure. Avian Dis 24: 120–138, 1980.CrossRefGoogle Scholar
  34. 34.
    Van Vleet JF, Ferrans VJ: Congestive cardiomyopathy induced in ducklings fed graded amounts of furazolidone. Am J Vet Res 44: 76–85, 1983.PubMedGoogle Scholar
  35. 35.
    Van Vleet JR, Ferrans VJ: Furazolidone-induced congestive cardiomyopathy in ducklings: regression of cardiac lesions after cessation of furazolidone ingestion. Am J Vet Res 44: 1007–1013, 1983.PubMedGoogle Scholar
  36. 36.
    Van Vleet JF, Ferrans VJ: Furazolidone-induced congestive cardiomyopathy in ducklings: myocardial ultrastructural alterations. Am J Vet Res 44: 1014 1023, 1983.Google Scholar
  37. 37.
    Van Vleet JF, Ferrans VJ: Furazolidone-induced congestive cardiomyopathy in ducklings: lack of protection from selenium, vitamin E, and taurine supplements. Am J Vet Res 44: 1143–1148, 1983.PubMedGoogle Scholar
  38. 38.
    Gwathmey J, Hamlin RL: Protection of turkeys against furazolidone-induced cardiomyopathy. Am J Cardiol 52: 626–631, 1983.PubMedCrossRefGoogle Scholar
  39. 39.
    Horowitz JD: Drugs that induce heart problems. Which agents? What effects? J Cardiovasc Med 8: 308–315, 1983.PubMedGoogle Scholar
  40. 40.
    McAllister HA Jr, Mullick FG: The cardiovascular system. In: Riddell R (ed) Pathology of drug-induced and toxic diseases. New York: Churchill-Livingstone, 1982, pp 201–228.Google Scholar
  41. 41.
    Fenoglio JJ Jr: The effects of drugs on the cardiovascular system. In: Silver MD (ed) Cardiovascular pathology. New York: Churchill-Livingstone, 1982, pp 1085–1107.Google Scholar
  42. 42.
    Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH: The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic and therapeutic considerations. Ann Intern Med 97: 7892, 1982.CrossRefGoogle Scholar
  43. 43.
    Graham JR: Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 254: 1–12, 1967.PubMedCrossRefGoogle Scholar
  44. 44.
    Kunkel RS: Fibrotic syndromes with chronic use of methysergide. Headache 11: 1–5, 1971.PubMedCrossRefGoogle Scholar
  45. 45.
    Bana DS, McNeal PS, Le Compte PM, Shah Y, Graham JR: Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88: 640–655, 1975.CrossRefGoogle Scholar
  46. 46.
    Mason JW, Billingham ME, Friedman JP: Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 56: 889–890, 1977.PubMedCrossRefGoogle Scholar
  47. 47.
    Ferrans VJ, Roberts WC: The carcinoid endocardial plaque: an ultrastructural study. Hum Pathol 7: 387409, 1976.Google Scholar
  48. 48.
    Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E: Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 57: 56–63, 1978.PubMedCrossRefGoogle Scholar
  49. 49.
    Suzuki T: Ultrastructural changes of heart muscle in cyanide poisoning. Tohoku J Exp Med 95: 271–287, 1968.PubMedCrossRefGoogle Scholar
  50. 50.
    Poche R: Über den Einfluss von Dinitrophenol und Thyroxin auf die Ultrastruktur des Herzmuskels bei der Ratte. Virchows Arch [Pathol Anat] 335: 28 2297, 1962.Google Scholar
  51. 51.
    Laguens R, Meckert PC, Segal A: Effects of acriflavin on the fine structure of the heart muscle cell mitochondria of normal and exercised rats. J Mol Cell Cardiol 4: 185–193, 1972.PubMedCrossRefGoogle Scholar
  52. 52.
    Raute-Kreinsen U, Beriet H, Bühler F, Rixner P: Elektronen-mikroskopische Befunde am Herzmuskel der Ratte bei experimentell induzierten Elektrolyt-veränderungen. Virchows Arch [Pathol Anat) 375: 33 1344, 1977.Google Scholar
  53. 53.
    Neinhaus H, Poche R, Reimold E: Elektrolytverschiebungen, histologische Veränderungen der Organe and Ultrastruktur des Herzmuskels nach Belastung mit Cortisol, Aldosteron und primären Natriumphosphat bei der Ratte. Virchows Arch [Pathol Anat] 337: 245–269, 1963.CrossRefGoogle Scholar
  54. 54.
    Ferrans VJ, Hibbs RG, Weily HS, Weilbaecher DG, Walsh J), Burch GE: A histochemical and electron microscopic study of epinephrine-induced myocardial necrosis. J Mol Cell Cardiol 1: 11–22, 1970.PubMedCrossRefGoogle Scholar
  55. 55.
    Kawanami O, Ferrans VJ, Fulmer JD, Crystal RG: Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab Invest 40: 717–734, 1979.PubMedGoogle Scholar
  56. 56.
    Ferrans VJ, Hibbs RG, Cipriano PR, Buja LM: Histochemical and electron microscopic studies of norepinephrine-induced myocardial necrosis in rats. Recent Adv Stud Card Struct Metab 1: 495–525, 1972.Google Scholar
  57. 57.
    Rona G, Hüttner I, Boutet M: Microcirculatory changes in myocardium with particular reference to catecholamine-induced cardiac muscle cell injury. In: Meesen H (ed) Handbuch der allgemeinen Pathologie, vol 3, part 7, Mikrozirkulation/Microcirculation. Berlin: Springer-Verlag, 1977, pp 791–888.Google Scholar
  58. 58.
    Berger JM, Bencosme SA: Divergence in patterns of atrial and ventricular cardiocyte degeneration: studies with plasmocid. J Mol Cell Cardiol 2: 41–49, 1971.PubMedCrossRefGoogle Scholar
  59. 59.
    Sarkar K, Levine DZ: Repair of the myocardial lesion during potassium repletion of kaliopenic rats: an ultrastructural study. J Mol Cell Cardiol 11: 1165 1172, 1979.Google Scholar
  60. 60.
    Ridout RM, Decker RS, Wildenthal K: Chloroquine-induced lysosomal abnormalities in cultured foetal mouse hearts. J Mol Cell Cardiol 10: 175–183, 1978.PubMedCrossRefGoogle Scholar
  61. 61.
    Trump BF, Berezesky IK, Laiho KU, Osornio AR, Mergner WJ, Smith MW: The role of calcium in cell injury: a review. Scan Electron Microsc II, SEM Inc, AMF O’Hare, Ill, 1980, pp 437–462.Google Scholar
  62. 62.
    Decker RS, Wildenthal K: Lysosomal abnormalities in hypoxic and reoxygenated hearts. I. Ultrastructural and cytochemical changes. Am J Pathol 98: 425–444, 1980.PubMedGoogle Scholar
  63. 63.
    Decker RS, Poole AR, Crie JS, Dingle JT, Wildenthal K: Lysosomal alterations in hypoxic and reoxygenated hearts. II. Immunohistochemical and biochemical changes in cathepsin D. Am J Pathol 98: 445–455, 1980.PubMedGoogle Scholar
  64. 64.
    Singal PK, Beamish RE, Dhalla NS: Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. In: Spitzer JJ (ed) Myocardial injury. New York: Plenum, 1982, pp 391–401.Google Scholar
  65. 65.
    Blackwell B, Marley E, Price J, Taylor D: Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 113: 349–365, 1967.PubMedCrossRefGoogle Scholar
  66. 66.
    Van Vleet JF, Amstutz HE, Weirich WE, Rebar AH, Ferrans VJ: Clinical, clinicopathologic, and pathologic alterations in monensin toxicosis in cattle. Am J Vet Res 44: 1629–1636, 1983.PubMedGoogle Scholar
  67. 67.
    Bhatnagar MK, Yamashiro S: Ultrastructural alterations of the myocardium of rats fed rapeseed oils. Res Vet Sci 26: 183–188, 1979.PubMedGoogle Scholar
  68. 68.
    Boor PJ, Ferrans VJ: Ultrastructural alterations in allylamine-induced cardiomyopathy: early lesions. Lab Invest 47: 76–86, 1982.PubMedGoogle Scholar
  69. 69.
    Clark AF, Tandler B, Vignos PJ: Glucocorticoid-induced alterations in the rabbit heart. Lab Invest 47: 603–610, 1982.PubMedGoogle Scholar
  70. 70.
    Van Vleet JF, Boon GD, Ferrans VJ: Induction of lesions of selenium—vitamin E deficiency in weanling swine fed silver, cobalt, tellurium, zinc, cadmium, and vanadium. Am J Vet Res 42: 789–799, 1981.Google Scholar
  71. 71.
    Van Vleet JF, Boon GD, Ferrans VJ: Induction of lesions of selenium—vitamin E deficiency in ducklings fed silver, cobalt, cadmium, copper, tellurium or zinc and protection by selenium or vitamin E supplements. Am J Vet Res 42: 1206–1217, 1981.PubMedGoogle Scholar
  72. 72.
    Herman EH, Balazs T, Ferrans VJ, Young RSK: Divergent effects of propranolol and furosemide pretreatment on acute cardiomyopathy induced by minoxidil in beagle dogs. Toxicology 20: 155–164, 1981.PubMedCrossRefGoogle Scholar
  73. 73.
    Herman EH, Ferrans VJ, Balazs T Minoxidil and cardiac lesions. Circulation 64: 1299–1300, 1981.PubMedCrossRefGoogle Scholar
  74. 74.
    Gans JH, Korson R, Cater MR, Ackerly CC: Effects of short-term and long-term theobromine administration to male dogs. Toxicol Appl Pharmacol 53: 481–496, 1980.PubMedCrossRefGoogle Scholar
  75. 75.
    Pinnell SR: Disorders of collagen. In: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds) The metabolic basis of inherited disease. New York: McGraw-Hill, 1978, pp 1366–1394.Google Scholar
  76. 76.
    Irey NS, Norris HJ: Intimai lesions associated with female reproductive steroids. Arch Pathol 96: 227234, 1973.Google Scholar
  77. 77.
    Arnett EN, Battle WE, Russo JV, Roberts WC: Intravenous injection of talc-containing drugs intended for oral use: a cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 60: 711–718, 1976.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • Victor J. Ferrans

There are no affiliations available

Personalised recommendations